Thompson Investment Management Inc. Acquires 35,325 Shares of Pfizer Inc. $PFE

Thompson Investment Management Inc. boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 8.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 463,455 shares of the biopharmaceutical company’s stock after buying an additional 35,325 shares during the period. Pfizer accounts for about 1.4% of Thompson Investment Management Inc.’s investment portfolio, making the stock its 16th biggest holding. Thompson Investment Management Inc.’s holdings in Pfizer were worth $11,540,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. State Street Corp lifted its stake in shares of Pfizer by 0.9% during the 3rd quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock worth $7,620,747,000 after purchasing an additional 2,786,098 shares during the last quarter. Northern Trust Corp grew its stake in Pfizer by 1.4% in the third quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company’s stock valued at $1,631,225,000 after purchasing an additional 869,175 shares during the last quarter. Fisher Asset Management LLC raised its holdings in Pfizer by 1.9% in the third quarter. Fisher Asset Management LLC now owns 49,288,054 shares of the biopharmaceutical company’s stock worth $1,255,860,000 after purchasing an additional 897,786 shares in the last quarter. Legal & General Group Plc raised its holdings in Pfizer by 8.6% in the third quarter. Legal & General Group Plc now owns 41,741,186 shares of the biopharmaceutical company’s stock worth $1,063,565,000 after purchasing an additional 3,296,415 shares in the last quarter. Finally, Amundi lifted its position in shares of Pfizer by 10.8% during the third quarter. Amundi now owns 41,490,929 shares of the biopharmaceutical company’s stock valued at $1,096,380,000 after buying an additional 4,043,413 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Shares of Pfizer stock opened at $27.03 on Monday. The company has a 50 day moving average price of $26.84 and a 200 day moving average price of $25.70. The firm has a market capitalization of $153.70 billion, a P/E ratio of 19.88 and a beta of 0.47. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.94.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. During the same quarter in the previous year, the firm earned $0.63 EPS. Pfizer’s revenue was down 1.2% compared to the same quarter last year. Sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Late‑stage clinical wins broaden Pfizer’s pipeline beyond COVID — a partnered 6‑valent Lyme vaccine showed ~75% Phase 3 efficacy and several oncology/immunology programs met key endpoints, supporting a re‑rating of growth prospects. Should Pfizer’s (PFE) New Lyme Vaccine and Oncology Wins Reshape Its Post‑COVID Pipeline Story?
• Positive Sentiment: Guggenheim raised its price target and reiterated a Buy, citing favorable risk/reward ahead of Phase 3 MEVPRO‑1 data — that analyst support can underpin short‑term investor interest. Guggenheim Sees Favorable Risk-Reward for Pfizer (PFE) Ahead of Phase 3 Data
• Positive Sentiment: Multiple bullish notes and “strong buy” theses are circulating after recent trial/portfolio progress, which can attract income and value investors looking for upside plus yield. Why Pfizer Remains A Strong Buy In 2026
• Neutral Sentiment: Jim Cramer mentioned PFE but said he needs more clarity on product flow — a reminder that mainstream TV coverage can move short‑term flows but hasn’t changed fundamentals. Jim Cramer on Pfizer: “I Just Need to Know Their Product Flow Better”
• Neutral Sentiment: Citi and other outlets continue to rate PFE around Hold/Neutral — signaling mixed analyst conviction despite select upgrades. Citi Remains a Hold on Pfizer (PFE)
• Negative Sentiment: A bearish view argues Wall Street overestimates PFE’s target price, pointing to political threats (e.g., “TrumpRx”, most‑favored‑nation pricing) that could compress margins and support a multi‑year earnings downside. That policy risk is pressuring valuation. Pfizer: Why Wall Street Habitually Overestimates Target Price
• Negative Sentiment: Income‑focused coverage flags payout safety concerns: Pfizer’s high yield draws attention but raises questions about sustainability if earnings weaken, which can amplify downside for dividend investors. Income Investors Face a Hard Truth About Pfizer’s Payout Safety

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. BMO Capital Markets reaffirmed an “outperform” rating and issued a $30.00 price objective on shares of Pfizer in a research report on Monday, March 9th. TD Cowen reissued a “hold” rating on shares of Pfizer in a research report on Tuesday, December 30th. Daiwa Securities Group downgraded shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price for the company. in a research note on Thursday, February 12th. Guggenheim upped their price target on Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $28.19.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.